Ticker
ACAD

Price
16.84
Stock movement down
-0.30 (-1.75%)
Company name
ACADIA Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
2.72B
Ent verdi
2.69B
Pris/omsetning
5.51
Pris/bok
6.11
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-1.98%
3 års avkastning
-15.41%
5 års avkastning
-12.00%
10 års avkastning
25.85%
Sist oppdatert: 2022-08-25

UTBYTTE

ACAD betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning5.51
Pris til bok6.11
EV i forhold til salg5.46

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall161.43M
EPS (TTM)-1.33
FCF per aksje (TTM)-0.88

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)493.06M
Bruttofortjeneste (TTM)475.66M
Driftsinntekter (TTM)-216.68M
Netto inntekt (TTM)-214.48M
EPS (TTM)-1.33
EPS (1 år fremover)-0.74

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)96.47%
Driftsmargin (TTM)-43.95%
Fortjenestemargin (TTM)-43.50%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter204.92M
Netto fordringer63.48M
Samlede omløpsmidler542.22M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler624.25M
Leverandørgjeld10.77M
Kortsiktig/nåværende langsiktig gjeld64.42M
Sum kortsiktig gjeld119.60M
Sum gjeld179.45M
Aksjonærenes egenkapital444.80M
Netto varige driftsmidler444.80M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-141.84M
Kapitalutgifter (TTM)47.00K
Fri kontantstrøm (TTM)-141.89M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-48.22%
Avkastning på eiendeler-34.36%
Avkastning på investert kapital-48.22%
Kontantavkastning på investert kapital-31.90%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning17.28
Daglig høy17.34
Daglig lav16.62
Daglig volum871K
Tidenes høyeste57.00
1 år analytikerestimat22.06
Beta0.72
EPS (TTM)-1.33
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon7 Nov 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACADS&P500
Nåværende prisfall fra toppnotering-70.46%-12.18%
Høyeste prisfall-96.29%-56.47%
Dato for høyeste fall12 Nov 20109 Mar 2009
Gj.snittlig fall fra topp-47.36%-11.38%
Gj.snittlig tid til ny topp50 days12 days
Maks tid til ny topp1820 days1805 days
SELSKAPSOPPLYSNINGER
ACAD (ACADIA Pharmaceuticals Inc) company logo
Markedsverdi
2.72B
Markedsverdi kategori
Mid-cap
Beskrivelse
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Ansatte
500
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Stephen R. Davis
Land
USA
By
San Diego
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
13. september 2022
SAN DIEGO, September 12, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of tro...
12. september 2022
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
7. september 2022
SAN DIEGO, September 01, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
1. september 2022
The mean of analysts' price targets for Acadia (ACAD) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...
30. august 2022
Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
26. august 2022
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) non-opioid painkiller. The company ...
9. august 2022
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
9. august 2022
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
8. august 2022
SAN DIEGO, August 08, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.
8. august 2022
Neste side